Renal Autologous Cell Therapy (REACT)
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Trial Timeline
Apr 25, 2018 → Nov 17, 2022
NCT ID
NCT03270956About Renal Autologous Cell Therapy (REACT)
Renal Autologous Cell Therapy (REACT) is a phase 2 stage product being developed by ProKidney for Type 2 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT03270956. Target conditions include Type 2 Diabetes Mellitus, Chronic Kidney Disease.
What happened to similar drugs?
20 of 20 similar drugs in Type 2 Diabetes Mellitus were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05286853 | Phase 3 | Withdrawn |
| NCT05918523 | Pre-clinical | Recruiting |
| NCT06790498 | Pre-clinical | Recruiting |
| NCT05694169 | Phase 1 | Terminated |
| NCT05018416 | Phase 2 | Completed |
| NCT04115345 | Phase 1 | Completed |
| NCT03270956 | Phase 2 | Completed |
| NCT02836574 | Phase 2 | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus